CCC

Cynata Therapeutics Ltd.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪25.30 M‬USD
−0.0361USD
‪−6.50 M‬USD
0.00USD
‪155.47 M‬
Beta (1Y)
−1.26

About CYNATA THERAPEUTICS LIMITED


CEO
Kilian Kelly
Website
Headquarters
Cremorne
Founded
2003
ISIN
AU000000CYP7
FIGI
BBG008P6RRX6
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYYNF is 0.1900 USD — it has increased by 72.73% in the past 24 hours. Watch Cynata Therapeutics Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Cynata Therapeutics Ltd. stocks are traded under the ticker CYYNF.
We've gathered analysts' opinions on Cynata Therapeutics Ltd. future price: according to them, CYYNF price has a max estimate of 0.49 USD and a min estimate of 0.49 USD. Watch CYYNF chart and read a more detailed Cynata Therapeutics Ltd. stock forecast: see what analysts think of Cynata Therapeutics Ltd. and suggest that you do with its stocks.
CYYNF reached its all-time high on Aug 2, 2019 with the price of 1.2500 USD, and its all-time low was 0.0720 USD and was reached on Oct 12, 2023. View more price dynamics on CYYNF chart.
See other stocks reaching their highest and lowest prices.
CYYNF stock is 42.11% volatile and has beta coefficient of −1.26. Track Cynata Therapeutics Ltd. stock price on the chart and check out the list of the most volatile stocks — is Cynata Therapeutics Ltd. there?
Today Cynata Therapeutics Ltd. has the market capitalization of ‪25.30 M‬, it has increased by 9.90% over the last week.
Yes, you can track Cynata Therapeutics Ltd. financials in yearly and quarterly reports right on TradingView.
Cynata Therapeutics Ltd. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
CYYNF net income for the last half-year is ‪−3.47 M‬ USD, while the previous report showed ‪−3.09 M‬ USD of net income which accounts for −12.20% change. Track more Cynata Therapeutics Ltd. financial stats to get the full picture.
No, CYYNF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYYNF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cynata Therapeutics Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cynata Therapeutics Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cynata Therapeutics Ltd. stock shows the sell signal. See more of Cynata Therapeutics Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.